ArticleFrontiers in medicine2024
Protective effect of
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric ulcer (GU), a globally prevalent disease, represents a significant burden to human health. Methods: This study utilized a rat model of chronic gastric ulceration induced by acetic acid to evaluate the protective effects of Results: The results suggest that the primary mechanism underlying BOS regulation of GU involves modulation of endogenous metabolites, including dimethylglycine, l-2,4-diaminobutyric acid, uridine propionic acid and l-asparagine. These diverse metabolites may have anti-inflammatory, antioxidant and reparative properties. In addition, KEGG enrichment analysis indicated potential anti-GU effects of BOS through diverse pathways such as energy metabolism, immune metabolism and amino acid metabolism. Conclusion: The study demonstrates BOS protective effects on GU in rats, potentially through modulating key metabolites and pathways, highlighting its therapeutic potential and warranting further investigation for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.